Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Dexamethasone for Pediatric Refractory/Secondary HLH
NCT03795909Phase 2Unknown
- Sponsor
- Capital Institute of Pediatrics
- Start
- Mar 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hemophagocytic lymphohistiocytosis (HLH) comparing Ruxolitinib + Dexamethasone with Placebo + Dexamethasone (2 arms). Primary endpoint: Severity of disease at 2 weeks. Status: unknown.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT03795909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795909.